Home » Stocks » OPKO Health

OPKO Health, Inc. (OPK)

Stock Price: $5.54 USD -0.13 (-2.21%)
Updated Aug 7, 2020 2:09 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 3.71B
Revenue (ttm) 965.79M
Net Income (ttm) -199.79M
Shares Out 669.83M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $5.54
Previous Close $5.66
Change ($) -0.13
Change (%) -2.21%
Day's Open 5.65
Day's Range 5.54 - 5.76
Day's Volume 6,015,981
52-Week Range 1.12 - 6.47

More Stats

Market Cap 3.71B
Enterprise Value 3.96B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 669.83M
Float 382.08M
EPS (basic) -0.33
EPS (diluted) -0.32
FCF / Share -0.24
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 129.49M
Short Ratio 9.49
Short % of Float 34.26%
Beta 2.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.84
PB Ratio 2.23
Revenue 965.79M
Operating Income -165.06M
Net Income -199.79M
Free Cash Flow -150.73M
Net Cash -248.37M
Net Cash / Share -0.37
Gross Margin 27.43%
Operating Margin -17.09%
Profit Margin -20.70%
FCF Margin -15.61%
ROA -1.92%
ROE -12.12%
ROIC -15.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
(44.53% upside)
Low
6.50
Current: $5.54
High
10.00
Target: 8.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9029909661,11749291.1396.5347.0427.9828.49
Revenue Growth-8.92%2.51%-13.56%127.25%439.63%-5.6%105.19%68.14%-1.81%-
Gross Profit32938634650625643.1247.6719.1710.7415.00
Operating Income-274-171-276-96.55-98.48-146-79.63-37.27-23.19-11.14
Net Income-315-153-305-48.36-30.03-172-114-29.05-1.28-18.93
Shares Outstanding595563559551488422355296281255
Earnings Per Share-0.53-0.27-0.55-0.10-0.06-0.41-0.32-0.11-0.01-0.08
Operating Cash Flow-173-109-92.0832.05164-90.38-55.65-25.42-18.50-18.71
Capital Expenditures-12.07-26.64-39.25-17.15-10.85-4.73-3.33-1.47-1.95-0.77
Free Cash Flow-185-136-13114.90153-95.11-58.98-26.89-20.45-19.49
Cash & Equivalents85.4596.4791.5016919496.9118627.3671.5218.02
Total Debt26194.7141.0955.6860.4514522417.538.7614.69
Net Cash / Debt-1751.7650.41113133-48.00-38.689.8462.763.33
Assets2,3092,4512,5902,7672,7991,2681,39229022977.85
Liabilities69566074667581943251986.5544.2228.67
Book Value1,6151,7911,8442,0921,98084287617916123.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name OPKO Health, Inc.
Country United States
Employees 6,096
CEO Phillip Frost

Stock Information

Ticker Symbol OPK
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: OPK
IPO Date November 2, 1995

Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.